

DIVI'S LABORATORIES LIMITED

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2007

(Rs.in Lakhs)

	Particulars	STAND ALONE			CONSOLIDATED		
		Unaudited	Unaudited	Audited	Unaudited	Unaudited	Audited
		Quarter ended 30.06.2007	Quarter Ended 30.06.2006	Year Ended 31.03.2007	Quarter ended 30.06.2007	Quarter Ended 30.06.2006	Year Ended 31.03.2007
(1)	(2)	(3)	(4)	(5)	(6)	(7)	
1	Net Sales/Income from operations (net of Excise Duty)	22807	16084	72442	22672	16069	72458
2	Other Income	344	436	1361	339	434	1343
3	Total Income:	23151	16520	73803	23011	16503	73801
4	Expenditure:						
	a. (Increase) / Decrease in Stock	(623)	437	1198	(680)	370	1056
	b. Consumption of Raw Material	10713	7758	31112	10658	7794	31253
	c. Staff Cost	1148	964	5158	1235	1040	5511
	d. Other Expenditure						
	- Manufacturing Expenses	1416	934	4381	1417	951	4392
	- Other expenses	1727	1384	5994	1813	1447	6372
5	Finance charges	337	206	1057	337	206	1058
6	Depreciation	861	426	2233	862	427	2235
7	Total Expenses:	15579	12109	51133	15641	12235	51877
8	Profit Before Tax (3-7)	7572	4411	22670	7370	4267	21924
	Provision for Taxation						
9	- Current Tax	485	1670	3332	485	1670	3333
	- Deferred Tax	355	63	137	391	31	-22
	- Fringe Benefit Tax	4	3	27	4	3	27
10	Net Profit: (8-9)	6728	2675	19174	6490	2563	18586
11	Paid-up Equity Share Capital	1291	1282	1291	1291	1282	1291
12	Reserves excluding revaluation reserves			52913			52250
13	Basic Earnings Per Share Rs.	52.11	20.86	149.54	50.27	20.00	144.95
	Diluted Earnings Per Share Rs. (Face Value : Rs.10 per share)	51.85	20.47	147.77	50.02	19.62	143.24
14	Aggregate of public shareholding:						
	- No. of shares	5998520	5903200	5998420	5998520	5903200	5998420
	- % of shareholding	46.46%	46.05%	46.46%	46.46%	46.05%	46.46%

NOTES:

1. The above results for the Quarter ended 30th June 2007, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 30th July, 2007.
2. The Consolidated results include the un-audited results of the subsidiaries, Divis Laboratories (USA) Inc., and Divi's Laboratories Europe AG.
3. The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 on Segment Reporting issued by the Institute of Chartered Accountants of India.
4. The company has charged an amount of Rs.226 lakhs during the current quarter towards Employee Compensation Expense on account of the outstanding stock options granted to eligible employees.
5. The figures for the previous year/period have been regrouped, wherever necessary.
6. Details of Investor complaints pursuant to Clause 41 of the Listing Agreement for the quarter ended 30.06.2007:
Opening: Nil, Received during the Quarter: 16, Resolved: 16, Closing: Nil

for Divi's Laboratories Limited

Place: Hyderabad
Date: 30th July, 2007

Dr. Murali K. Divi
Chairman & Managing Director